GSK Swaps Cancer For Vaccines As It Sheds Legacy Products, Not R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
Complex transaction with Novartis leaves the British drug maker with a better balanced portfolio centered on vaccines, consumer health, respiratory and HIV medicines.